Skip to main content
Erschienen in: Journal of General Internal Medicine 3/2014

01.08.2014 | Original Research

The Rare Diseases Clinical Research Network’s Organization and Approach to Observational Research and Health Outcomes Research

verfasst von: Jeffrey P. Krischer, Ph.D., Rashmi Gopal-Srivastava, Ph.D., Stephen. C. Groft, Pharm.D., David J. Eckstein, Ph.D., for the Rare Diseases Clinical Research Network

Erschienen in: Journal of General Internal Medicine | Sonderheft 3/2014

Einloggen, um Zugang zu erhalten

ABSTRACT

Established in 2003 by the Office of Rare Diseases Research (ORDR), in collaboration with several National Institutes of Health (NIH) Institutes/Centers, the Rare Diseases Clinical Research Network (RDCRN) consists of multiple clinical consortia conducting research in more than 200 rare diseases. The RDCRN supports longitudinal or natural history, pilot, Phase I, II, and III, case–control, cross-sectional, chart review, physician survey, bio-repository, and RDCRN Contact Registry (CR) studies. To date, there have been 24,684 participants enrolled on 120 studies from 446 sites worldwide. An additional 11,533 individuals participate in the CR. Through a central data management and coordinating center (DMCC), the RDCRN’s platform for the conduct of observational research encompasses electronic case report forms, federated databases, and an online CR for epidemiological and survey research. An ORDR-governed data repository (through dbGaP, a database for genotype and phenotype information from the National Library of Medicine) has been created. DMCC coordinates with ORDR to register and upload study data to dbGaP for data sharing with the scientific community. The platform provided by the RDCRN DMCC has supported 128 studies, six of which were successfully conducted through the online CR, with 2,352 individuals accrued and a median enrollment time of just 2 months. The RDCRN has built a powerful suite of web-based tools that provide for integration of federated and online database support that can accommodate a large number of rare diseases on a global scale. RDCRN studies have made important advances in the diagnosis and treatment of rare diseases.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Health Promotion and Disease Prevention Amendments of 1984, Pub. L. No. 98‐551, 98 Stat. 2815 (Oct. 30, 1984). Health Promotion and Disease Prevention Amendments of 1984, Pub. L. No. 98‐551, 98 Stat. 2815 (Oct. 30, 1984).
2.
Zurück zum Zitat Hampton T. Rare disease research gets boost. JAMA. 2006;295(24):2836–2838.PubMed Hampton T. Rare disease research gets boost. JAMA. 2006;295(24):2836–2838.PubMed
3.
Zurück zum Zitat Akers A, Ball KL, Clancy M, et al. the Brain Vascular Malformation Consortium. Brain Vascular Malformation Consortium: overview, progress, and future directions. J Rare Disorders. 2013;1(1):1–15.CrossRef Akers A, Ball KL, Clancy M, et al. the Brain Vascular Malformation Consortium. Brain Vascular Malformation Consortium: overview, progress, and future directions. J Rare Disorders. 2013;1(1):1–15.CrossRef
4.
Zurück zum Zitat Chronic Graft Versus Host Disease Consortium. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant. 2011;17(8):1114–1120.CrossRef Chronic Graft Versus Host Disease Consortium. Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD. Biol Blood Marrow Transplant. 2011;17(8):1114–1120.CrossRef
5.
Zurück zum Zitat Gadegbeku CA, Gipson DS, Holzman LB, et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013;83(4):749–756.PubMedCentralPubMedCrossRef Gadegbeku CA, Gipson DS, Holzman LB, et al. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013;83(4):749–756.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Richesson RL, Malloy JF, Paulus K, Cuthbertson D, Krischer JP. An automated standardized system for managing adverse events in clinical research networks. Drug Saf. 2008;31(10):807–822.PubMedCrossRef Richesson RL, Malloy JF, Paulus K, Cuthbertson D, Krischer JP. An automated standardized system for managing adverse events in clinical research networks. Drug Saf. 2008;31(10):807–822.PubMedCrossRef
7.
Zurück zum Zitat Richesson RL, Lee HS, Cuthbertson D, Lloyd J, Young K, Krischer JP. An automated communications system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants. Contemp Clin Trials. 2009;30(1):55–62.PubMedCentralPubMedCrossRef Richesson RL, Lee HS, Cuthbertson D, Lloyd J, Young K, Krischer JP. An automated communications system in a contact registry for persons with rare diseases: scalable tools for identifying and recruiting clinical research participants. Contemp Clin Trials. 2009;30(1):55–62.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Richesson RL, Sutphen R, Shereff D, Krischer JP. The rare diseases clinical research network contact registry update: features and functionality. Contemp Clin Trials. 2012;33(4):647–656.PubMedCentralPubMedCrossRef Richesson RL, Sutphen R, Shereff D, Krischer JP. The rare diseases clinical research network contact registry update: features and functionality. Contemp Clin Trials. 2012;33(4):647–656.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Clowse ME, Richeson RL, Pieper C, Merkel PA. for the Vasculitis Clinical Research Consortium. Pregnancy outcomes among patients with vasculitis. Arthritis Care Res. 2013;65(8):1370–1374.CrossRef Clowse ME, Richeson RL, Pieper C, Merkel PA. for the Vasculitis Clinical Research Consortium. Pregnancy outcomes among patients with vasculitis. Arthritis Care Res. 2013;65(8):1370–1374.CrossRef
10.
Zurück zum Zitat McCormack FX, Inoue Y, Moss J, Singer LG, et al. the National Institutes of Health Rare Lung Diseases Consortium; the MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–1606.PubMedCentralPubMedCrossRef McCormack FX, Inoue Y, Moss J, Singer LG, et al. the National Institutes of Health Rare Lung Diseases Consortium; the MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011;364(17):1595–1606.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung. 2012;190(5):523–527.PubMedCrossRef Couluris M, Kinder BW, Xu P, Gross-King M, Krischer J, Panos RJ. Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project. Lung. 2012;190(5):523–527.PubMedCrossRef
12.
Zurück zum Zitat Statland JM, Bundy BN, Wang Y, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308(13):1357–1365.PubMedCentralPubMedCrossRef Statland JM, Bundy BN, Wang Y, et al. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308(13):1357–1365.PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Resp. Crit Care Med. 2013;188(8):913–922. Knowles MR, Daniels LA, Davis SD, Zariwala MA, Leigh MW. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Resp. Crit Care Med. 2013;188(8):913–922.
14.
Zurück zum Zitat Abrams JS, Mooney MM, Zwiebel JA, et al. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. JNCI. 2013;105(13):954–959.PubMedCrossRef Abrams JS, Mooney MM, Zwiebel JA, et al. Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. JNCI. 2013;105(13):954–959.PubMedCrossRef
15.
Zurück zum Zitat Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–26.PubMedCentralPubMedCrossRef Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009;96(1):20–26.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Richesson R, Syed A, Guillette H, Tuttle MS, Krischer J. A web-based SNOMED CT browser: distributed and real-time use of SNOMED CT during the clinical research process. Stud Health Technol Inform. 2007;129(Pt 1):631–635.PubMed Richesson R, Syed A, Guillette H, Tuttle MS, Krischer J. A web-based SNOMED CT browser: distributed and real-time use of SNOMED CT during the clinical research process. Stud Health Technol Inform. 2007;129(Pt 1):631–635.PubMed
17.
Zurück zum Zitat Richesson RL, Smith SB, Malloy J, Krischer JP. Achieving standardized medication data in clinical research studies: two approaches and applications for implementing RxNorm. J Med Syst. 2010;34(4):651–657.PubMedCentralPubMedCrossRef Richesson RL, Smith SB, Malloy J, Krischer JP. Achieving standardized medication data in clinical research studies: two approaches and applications for implementing RxNorm. J Med Syst. 2010;34(4):651–657.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Richesson RL, Nadkarni P. Data standards for clinical research data collection forms: current status and challenges. J Am Med Inform Assoc. 2011;18(3):341–346.PubMedCentralPubMedCrossRef Richesson RL, Nadkarni P. Data standards for clinical research data collection forms: current status and challenges. J Am Med Inform Assoc. 2011;18(3):341–346.PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651–4657.PubMedCentralPubMedCrossRef Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood. 2011;117(17):4651–4657.PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Pidala J, Kurland BF, Chai X, et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica. 2011;96(10):1528–1535.PubMedCentralPubMedCrossRef Pidala J, Kurland BF, Chai X, et al. Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium. Haematologica. 2011;96(10):1528–1535.PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Burns J, Ramchandren S, Ryan MM, et al. Determinants of reduced health-related quality of life in pediatric inherited neuropathies. Neurology. 2010;75(8):726–731.PubMedCentralPubMedCrossRef Burns J, Ramchandren S, Ryan MM, et al. Determinants of reduced health-related quality of life in pediatric inherited neuropathies. Neurology. 2010;75(8):726–731.PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Burns J, Ryan MM, Ouvrier RA. Quality of life in children with Charcot-Marie-Tooth disease. J Child Neurol. 2010;25(3):343–347.PubMedCrossRef Burns J, Ryan MM, Ouvrier RA. Quality of life in children with Charcot-Marie-Tooth disease. J Child Neurol. 2010;25(3):343–347.PubMedCrossRef
23.
Zurück zum Zitat Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2011;63(7):1055–1061.CrossRef Walsh M, Mukhtyar C, Mahr A, et al. Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2011;63(7):1055–1061.CrossRef
24.
Zurück zum Zitat Tomasson G, Boers M, Walsh M, et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res. 2012;64(2):273–279.CrossRef Tomasson G, Boers M, Walsh M, et al. Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res. 2012;64(2):273–279.CrossRef
25.
Zurück zum Zitat Lane JB, Lee HS, Smith LW, et al. Clinical severity and quality of life in children and adolescents with Rett syndrome. Neurology. 2011;77(20):1812–1818.PubMedCentralPubMedCrossRef Lane JB, Lee HS, Smith LW, et al. Clinical severity and quality of life in children and adolescents with Rett syndrome. Neurology. 2011;77(20):1812–1818.PubMedCentralPubMedCrossRef
26.
Zurück zum Zitat Herlyn K, Hellmich B, Seo P, Merkel PA. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res. 2010;62(11):1639–1645.CrossRef Herlyn K, Hellmich B, Seo P, Merkel PA. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res. 2010;62(11):1639–1645.CrossRef
27.
Zurück zum Zitat Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord. 2010;20(12):839–846.PubMedCrossRef Reilly MM, Shy ME, Muntoni F, Pareyson D. 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT). Neuromuscul Disord. 2010;20(12):839–846.PubMedCrossRef
28.
Zurück zum Zitat Groft SC, Gopal-Srivastava R. A model for collaborative clinical research in rare diseases: experience from the Rare Disease Clinical Research Network program. J Clin Invest. 2013;3(11):1015–21. Groft SC, Gopal-Srivastava R. A model for collaborative clinical research in rare diseases: experience from the Rare Disease Clinical Research Network program. J Clin Invest. 2013;3(11):1015–21.
Metadaten
Titel
The Rare Diseases Clinical Research Network’s Organization and Approach to Observational Research and Health Outcomes Research
verfasst von
Jeffrey P. Krischer, Ph.D.
Rashmi Gopal-Srivastava, Ph.D.
Stephen. C. Groft, Pharm.D.
David J. Eckstein, Ph.D.
for the Rare Diseases Clinical Research Network
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe Sonderheft 3/2014
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-014-2894-x

Weitere Artikel der Sonderheft 3/2014

Journal of General Internal Medicine 3/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.